Summit Therapeutics Inc. (NASDAQ:SMMT) announced that The Lancet Oncology published primary analysis results from its global Phase 3 HARMONi trial.
Significant Progression-Free Survival Improvements
The study evaluated ivonescimab combined with platinum-doublet chemotherapy against a placebo and chemotherapy regimen.
This treatment targets patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) who experienced disease progression after using a third-generation EGFR tyrosine kinase inhibitor.
The trial data showed that patients receiving the ivonescimab combination experienced a median progression-free survival (PFS) of 6.8 months, compared to 4.4 months for the placebo group.
